Toliman Pamela J, Kaldor John M, Badman Steven G, Gabuzzi Josephine, Silim Selina, Kumbia Antonia, Kombuk Benny, Kombati Zure, Munnull Gloria, Guy Rebecca, Vallely Lisa M, Kelly-Hanku Angela, Wand Handan, Ryan Claire, Tan Grace, Brotherton Julia, Saville Marion, Mola Glen D L, Garland Suzanne M, Tabrizi Sepehr N, Vallely Andrew J
Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea; Kirby Institute, UNSW Sydney, Australia.
Kirby Institute, UNSW Sydney, Australia.
Papillomavirus Res. 2018 Dec;6:70-76. doi: 10.1016/j.pvr.2018.10.009. Epub 2018 Nov 1.
The performance of different clinical screening algorithms comprising point-of-care HPV-DNA testing using self-collected vaginal ('V') specimens, and visual inspection of the cervix with acetic acid (VIA) was evaluated in Papua New Guinea. Women aged 30-59 years provided V specimens that were tested at point-of-care using the Xpert HPV Test (Cepheid, Sunnyvale, CA). A clinician-collected cervical ('C') specimen was then collected for point-of-care Xpert testing, and liquid-based cytology (LBC). Following this, VIA examination was conducted, blind to HPV test results, and ablative cervical cryotherapy provided if indicated. Detection of high-grade squamous intraepithelial lesion (HSIL) by LBC was the reference standard used to evaluate clinical screening algorithms. Of 1005 women, 36 had HSIL+. Xpert HPV Test performance using V specimens (sensitivity 91.7%, specificity 87.0%, PPV 34.0%, NPV 99.3%) was superior to VIA examination alone (51.5%, 81.4%, 17.5%, 95.6% respectively) in predicting underlying HSIL+. A screening algorithm comprising V specimen HPV testing followed by VIA examination had low sensitivity (45.5%) but comparable specificity, PPV and NPV to HPV testing alone (96.3%, 45.5%, 96.3% respectively). A 'test-and-treat' screening algorithm based on point-of-care HPV testing of V specimens had superior performance compared with either VIA examination alone, or a combined screening algorithm comprising HPV testing plus VIA.
在巴布亚新几内亚,对不同的临床筛查算法进行了评估,这些算法包括使用自行采集的阴道(“V”)标本进行即时护理HPV-DNA检测,以及用醋酸对子宫颈进行视诊(VIA)。30至59岁的女性提供了V标本,使用Xpert HPV检测(赛沛公司,加利福尼亚州桑尼维尔)在即时护理时进行检测。然后采集临床医生收集的子宫颈(“C”)标本用于即时护理Xpert检测和液基细胞学检查(LBC)。在此之后,进行VIA检查,检查时不了解HPV检测结果,如果有指征则提供消融性子宫颈冷冻治疗。通过LBC检测高级别鳞状上皮内病变(HSIL)是用于评估临床筛查算法的参考标准。在1005名女性中,36人患有HSIL+。在预测潜在的HSIL+方面,使用V标本的Xpert HPV检测表现(敏感性91.7%,特异性87.0%,阳性预测值34.0%,阴性预测值99.3%)优于单独的VIA检查(分别为51.5%、81.4%、17.5%、95.6%)。一种包括V标本HPV检测然后进行VIA检查的筛查算法敏感性较低(45.5%),但特异性、阳性预测值和阴性预测值与单独的HPV检测相当(分别为96.3%、45.5%、96.3%)。基于V标本即时护理HPV检测的“检测即治疗”筛查算法与单独的VIA检查或包括HPV检测加VIA的联合筛查算法相比,表现更优。